GHRP-6

What Is GHRP-6?#

Growth Hormone Releasing Peptide-6 (GHRP-6) is a synthetic hexapeptide with the amino acid sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of 873.01 Da. It acts primarily through the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. GHRP-6 was developed in the late 1980s and early 1990s and was one of the first synthetic growth hormone secretagogues to be extensively characterized in both laboratory and clinical research settings.

The peptide's CAS number is 87616-84-0 and its molecular formula is C46H56N12O6. GHRP-6 contains two D-amino acids (D-Trp at position 2 and D-Phe at position 5), which distinguish it from naturally occurring peptide sequences and contribute to its protease resistance and receptor binding properties. The C-terminus is amidated (-NH2), which protects against carboxypeptidase degradation and enhances receptor binding affinity.

GHRP-6 is distinct from growth hormone releasing hormone (GHRH) analogs such as sermorelin or CJC-1295. While GHRH acts through the GHRH receptor (GHRH-R) to stimulate GH synthesis and release, GHRP-6 operates through the GHS-R1a receptor via a complementary mechanism. When administered together, GHRP-6 and GHRH analogs produce a synergistic GH response that substantially exceeds the sum of their individual effects, a pharmacological property that has been demonstrated in multiple clinical studies and has significant implications for research into GH deficiency and related conditions.

GHRP-6 is not approved by the FDA, EMA, or any other major regulatory agency for human therapeutic use. It is classified as a research chemical and has been used primarily as a pharmacological tool in clinical research settings.

Mechanism of Action#

GHRP-6 stimulates GH release through multiple interconnected mechanisms at both the hypothalamic and pituitary levels:

GHS-R1a Receptor Activation#

GHRP-6 binds to and activates the growth hormone secretagogue receptor 1a (GHS-R1a) on somatotroph cells in the anterior pituitary gland. This receptor is a G-protein coupled receptor (GPCR) that, upon activation, triggers intracellular signaling cascades involving phospholipase C, inositol trisphosphate (IP3) production, and intracellular calcium release from the endoplasmic reticulum. The resulting increase in intracellular calcium concentration stimulates the exocytosis of GH-containing secretory granules.

A key study by Cheng et al. (1995, PMID: 7772238) demonstrated that GHRP-6 stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells, confirming the involvement of phospholipase C signaling in the GH release mechanism.

Hypothalamic Actions#

GHRP-6 also acts at the hypothalamic level, where it promotes the release of endogenous GHRH from GHRH-producing neurons. Popovic et al. (1995, PMID: 7883854) demonstrated that patients with hypothalamic-pituitary disconnection showed complete blockade of GHRP-6-induced GH secretion, providing strong evidence that the hypothalamic component is essential for the full GH-releasing effect.

Pandya et al. (1998, PMID: 9543138) further established that GHRP-6 requires endogenous hypothalamic GHRH for maximal GH stimulation. In the absence of GHRH signaling, the GH response to GHRP-6 is significantly attenuated, confirming that the peptide's mechanism involves amplification of the endogenous GHRH-GHRH-R axis.

Somatostatin Antagonism#

GHRP-6 functionally antagonizes the GH-inhibiting effects of somatostatin. Somatostatin is the primary inhibitor of GH secretion, acting at both the hypothalamic and pituitary levels. GHRP-6's ability to overcome somatostatin inhibition is particularly relevant because it allows GH release even during periods when somatostatin tone is normally high.

Appetite Stimulation#

As a GHS-R1a agonist, GHRP-6 mimics ghrelin's orexigenic (appetite-stimulating) effects. GHS-R1a is expressed in the hypothalamic arcuate nucleus on neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons, which are the primary appetite-stimulating pathways. GHRP-6 activation of these neurons produces a strong hunger signal, which is one of its most noticeable acute effects. This appetite stimulation is more pronounced with GHRP-6 than with later-generation GHS peptides such as ipamorelin.

GH Secretagogue Classification#

GHRP-6 belongs to the growth hormone secretagogue (GHS) family, which includes both peptide and non-peptide compounds that activate the GHS-R1a receptor:

GHRP-6 is distinguished from later-generation GHS compounds by its relatively strong appetite-stimulating effect and its less selective hormonal profile. At higher doses, GHRP-6 stimulates cortisol and prolactin release in addition to GH, effects that are generally undesirable and that have been minimized in later compounds like ipamorelin.

Research Applications#

GH Axis Diagnostic Testing#

GHRP-6 has been used extensively as a diagnostic tool to assess pituitary GH reserve:

• GH deficiency diagnosis: GHRP-6 stimulation testing can distinguish between hypothalamic and pituitary causes of GH deficiency
• GH reserve assessment: The magnitude of the GH response to GHRP-6 reflects the functional capacity of pituitary somatotrophs
• Combined GHRP-6 + GHRH testing: The synergistic response provides a highly sensitive test for GH secretory capacity

Cytoprotective Research#

One of the most significant research findings for GHRP-6 is its cytoprotective properties, which appear to be at least partially independent of GH release. Berlanga et al. (2006, PMID: 16417467) demonstrated that GHRP-6 protects against multiple organ failure in animal models through mechanisms involving:

• Cardiac protection: Reduction of infarct size in ischemia-reperfusion models
• Hepatic protection: Reduction of liver damage markers in ischemia models
• Anti-inflammatory effects: Reduction of inflammatory cytokine production
• Anti-apoptotic effects: Activation of pro-survival signaling pathways

These cytoprotective effects are mediated at least in part through the CD36 receptor (a class B scavenger receptor), which is a second receptor target for GHRP-6 and other GHS peptides, distinct from GHS-R1a.

Sleep and Circadian Research#

Frieboes et al. (1999, PMID: 10336729) studied the effects of GHRP-6 on nocturnal GH, ACTH, and cortisol secretion as well as on sleep EEG patterns. The findings demonstrated that GHRP-6 administration affects sleep architecture and hormonal secretion patterns, providing insights into the relationship between GH secretion, the ghrelin system, and sleep regulation.

Thyroid Function Interactions#

Pimentel-Filho et al. (1997, PMID: 9156038) investigated GH responses to GHRP-6 in hypothyroid patients, demonstrating that thyroid status affects the sensitivity of the GH axis to GHRP-6 stimulation. This has implications for understanding the interplay between thyroid and GH axes.

Safety Considerations#

GHRP-6 is not approved for human therapeutic use. Key safety considerations from clinical research include:

• Cortisol elevation: GHRP-6 can increase cortisol secretion at higher doses, which is undesirable for chronic use
• Prolactin elevation: Prolactin increases have been observed, though they are typically modest
• Appetite stimulation: The strong orexigenic effect can cause significant hunger
• Water retention: Some degree of water retention has been reported
• Insulin sensitivity: GH elevation may affect glucose metabolism

Evidence Gaps and Limitations#

• No Phase 3 clinical trials for any therapeutic indication
• Cytoprotective effects established primarily in animal models; limited human data
• Long-term safety data from controlled human studies is unavailable
• Optimal dosing protocols for specific research applications not standardized
• The relative contribution of GHS-R1a vs CD36 receptor signaling to cytoprotective effects is not fully resolved
• Whether GHRP-6's appetite-stimulating effects can be pharmacologically separated from GH-releasing effects is unclear
• Potential for GH axis desensitization with chronic use has not been definitively characterized

Key Research Findings#

Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction, published in Clinical Science (Berlanga J et al., 2007; PMID: 16989643):

• GHRP-6 reduced infarct size by 78% in porcine model

Related Reading#

• GHRP-6 research studies and evidence
• GHRP-6 dosing protocols
• GHRP-6 side effects profile
• GHRP-2 research guide
• Hexarelin research guide